CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,581 enrolled
Drug / intervention
AntiVEGF +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06119347
NCT06119347N/ACompleted
CompareCT.gov

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study

First Affiliated Hospital of Wenzhou Medical University·observational·Posted Nov 7, 2023·Updated Nov 8, 2023

In Brief

An observational study evaluating AntiVEGF and ICIs for AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs. Completed, enrolled 1,581 participants across 1 site.

Detailed Summary

The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs). The main question it aims to answer is whether the choice between AntiVEGF and ICIs affects the risks of acute kidney injury in cancer patients. Cancer patients receiving AntiVEGF will be compared to those treated with ICIs to see if the AKI incidence is higher in patients receiving ICIs.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 7, 2023
Enrollment StartJan 1, 2020
Primary CompletionJun 30, 2023
Study CompletionOct 10, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 2.7 years ago

Interventions

AntiVEGFdrug

anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;

ICIsdrug

immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.